Literature DB >> 11129327

Regulation of CD40L expression on natural killer cells by interleukin-12 and interferon gamma: its role in the elicitation of an effective antitumor immune response.

M D Jyothi1, A Khar.   

Abstract

Effector cell functions are regulated by a number of positive signals for the mediation of antitumor immunity. The CD40 and CD40 ligand (CD40L) interaction has been implicated in the generation of effective cell-mediated and humoral immune responses, where cytokines have been shown to play a significant role in the expression of these molecules. Our earlier studies have shown that spontaneous regression of a rat histiocytoma transplanted s.c. is mediated by CD8 + CD3- NK cells. The CD40-CD40L mediation during tumor regression was of interest. Tumor-transplanted animals showed enhanced expression of CD40L on natural killer (NK) and T cells, when compared to cells from normal animals. CD40 expression on AK-5 tumor cells was also induced after s.c. transplantation. Administration of anti-(interleukin-12) (anti-IL-12) and anti-(interferon gamma) (anti-IFNgamma) antibodies in tumor-bearing animals showed down-regulation of the expression of CD40L on NK and T cells with simultaneous inhibition of cytotoxic acitivity of NK cells, cytokine release and the production of antitumor antibody. Naive NK cells, when co-cultured with fixed AK-5 cells, were induced to express CD40L. CD40L expression modulated the immune response exerted by NK cells, in part by the activation of nuclear factor kB (NF-kB). Furthermore, the signaling via CD40L through the use of anti-CD40L antibody promoted the in vitro activation of cytotoxic as well as NF-kappaB binding activity in NK cells from tumor-transplanted animals. These observations demonstrate that the expression of CD40L by the effector cells is regulated by IL-12 and IFNgamma, and could effectively modulate the NK-cell-mediated immune response during the regression of AK-5 tumor.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11129327     DOI: 10.1007/s002620000151

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  9 in total

Review 1.  T-cell-independent antitumor effects of CD40 ligation.

Authors:  Alexander L Rakhmilevich; Kory L Alderson; Paul M Sondel
Journal:  Int Rev Immunol       Date:  2012-08       Impact factor: 5.311

2.  LNFPIII/LeX-stimulated macrophages activate natural killer cells via CD40-CD40L interaction.

Authors:  Olga Atochina; Donald Harn
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

3.  Opposing roles of NF-kappaB family members in the regulation of NK cell proliferation and production of IFN-gamma.

Authors:  Cristina M Tato; Nicola Mason; David Artis; Sagi Shapira; Jorge C Caamano; Jay H Bream; Hsiou-Chi Liou; Christopher A Hunter
Journal:  Int Immunol       Date:  2006-02-15       Impact factor: 4.823

4.  CD40 contributes to lethality in acute sepsis: in vivo role for CD40 in innate immunity.

Authors:  Jeffrey A Gold; Merdad Parsey; Yoshihiko Hoshino; Satomi Hoshino; Anna Nolan; Herman Yee; Doris B Tse; Michael D Weiden
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

5.  CD40 signaling to the rescue: A CD8 exhaustion perspective in chronic infectious diseases.

Authors:  Rajarshi Bhadra; Dustin A Cobb; Imtiaz A Khan
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

6.  Cd40 but not CD154 knockout mice have reduced inflammatory response in polymicrobial sepsis: a potential role for Escherichia coli heat shock protein 70 in CD40-mediated inflammation in vivo.

Authors:  Anna Nolan; Michael D Weiden; Yoshihiko Hoshino; Jeffrey A Gold
Journal:  Shock       Date:  2004-12       Impact factor: 3.454

7.  Multifunctional CD40L: pro- and anti-neoplastic activity.

Authors:  Aleksandra Korniluk; Halina Kemona; Violetta Dymicka-Piekarska
Journal:  Tumour Biol       Date:  2014-08-13

Review 8.  Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer.

Authors:  Johanna Bödder; Tasmin Zahan; Rianne van Slooten; Gerty Schreibelt; I Jolanda M de Vries; Georgina Flórez-Grau
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

Review 9.  NF-κB in Cancer Immunity: Friend or Foe?

Authors:  Guilhem Lalle; Julie Twardowski; Yenkel Grinberg-Bleyer
Journal:  Cells       Date:  2021-02-09       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.